Abstract
Ten percent of paragangliomas are malignant and one-third occurs in a genetic background. We report a case of succinate dehydrogenase subunit B (SDHB)-related malignant paraganglioma with dramatic response to temozolomide and capecitabine regimen (decrease in tumor size of 70% with RECIST criteria). Tumor cells harbored a new mutation in SDHB gene and showed aberrant hypermethylation of O6-methylguanine-DNA-methyltransferase promoter. Our report suggests the importance of molecular predictive factors of response for the selection of chemotherapeutic as well as targeted agents. This observation points to a possible genotype response to treatment relationships, which could help to design tailor-made treatments in the future.
Original language | English |
---|---|
Pages (from-to) | 1107-1111 |
Number of pages | 5 |
Journal | European Journal of Endocrinology |
Volume | 166 |
Issue number | 6 |
DOIs | |
Publication status | Published - 1 Jun 2012 |
Externally published | Yes |